Business Context and Reporting Period
Company: Accuray Incorporated (Accuray)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2010
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used to treat solid tumors anywhere in the body. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of December 31, 2010, there were 222 CyberKnife systems installed at customer sites.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2010 | Six Months Ended Dec 31, 2010 | Balance Sheet (Dec 31, 2010) |
|---|---|---|---|
| Total Net Revenue | $54,246 | $92,314 | - |
| Gross Profit | $29,466 | $47,703 | - |
| Gross Margin | 54.3% | 51.7% | - |
| Net Income (Loss) | $4,098 | $(542) | - |
| Operating Income (Loss) | $3,685 | $(2,444) | - |
| Cash and Cash Equivalents | - | - | $49,513 |
| Short-term Investments | - | - | $102,427 |
| Total Current Assets | - | - | $230,964 |
| Total Current Liabilities | - | - | $73,894 |
| Accumulated Deficit | - | - | $(118,245) |
Liquidity: The company reported $151.9 million in total cash, cash equivalents, and marketable securities as of December 31, 2010. Net cash provided by operating activities was $0.2 million for the six months ended December 31, 2010, compared to a use of $8.9 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Decline: Total net revenue decreased 5% ($3.1 million) for the three months ended December 31, 2010, compared to the same period in 2009. For the six-month period, revenue decreased 14% ($15.6 million). This decline was primarily driven by a reduction in product revenue and service revenue recognized from legacy "Platinum" service plans, which are being phased out.
- Profitability Improvement: Despite the revenue decline, the company reported a net income of $4.1 million for the quarter, compared to a net loss of $1.2 million in the prior year quarter. This turnaround was driven by improved gross margins (up to 54.3% from 45.3%) and significant reductions in operating expenses.
- Expense Reductions: Selling and marketing expenses decreased 21% ($2.1 million) and General and Administrative expenses decreased 19% ($1.9 million) for the quarter, largely due to reduced stock-based compensation, lower headcount, and decreased legal fees related to ongoing litigation.
- R&D Increase: Research and development expenses increased 20% ($1.5 million) for the quarter due to increased consulting fees and workforce expenses to support product advancement.
Guidance, Outlook, and Risks
Management Commentary:
- Revenue Mix: Management expects non-Platinum revenue to continue growing while legacy Platinum revenue decreases as these arrangements lapse. Service revenue is expected to increase as the installed base grows.
- Backlog: Total backlog was approximately $410.2 million as of December 31, 2010, up from $325.3 million in the prior year. This includes $160.5 million in CyberKnife system sales and $249.7 million in service plans.
- Siemens Alliance: Accuray entered a strategic alliance with Siemens AG in June 2010. As of the reporting date, little development work had occurred on the joint "Cayman Products" due to delays in agreeing on specifications and Siemens' internal reorganization.
Risks and Contingencies:
- Legal Proceedings: The company is involved in a securities class action lawsuit and a shareholder derivative lawsuit. Additionally, Best Medical International, Inc. has filed patent infringement lawsuits against Accuray. No liabilities have been recorded as losses are not deemed probable or estimable.
- Reimbursement: The company faces risks related to Medicare reimbursement rates. For 2011, certain rates decreased slightly, which could impact customer purchasing decisions.
- Regulatory: Future product modifications may require new FDA 510(k) clearances. The company submitted one recall report to the FDA in the quarter regarding treatment plan evaluation, though costs were immaterial.
- Supply Chain: Accuray relies on single-source suppliers for critical components (e.g., robotic manipulator, magnetron), creating potential supply chain risks.
Key Facts for Investor Verification
- Revenue Recognition Timing: Verify the impact of the phase-out of legacy "Platinum" service plans on future revenue recognition, as these plans required deferral of revenue until upgrade obligations were met.
- Siemens Alliance Progress: Monitor the status of the strategic alliance with Siemens AG, specifically the development timeline for "Cayman Products" and any milestone payments.
- Legal Exposure: Track the status of the Best Medical International patent infringement lawsuits and the securities class action litigation to assess potential future liabilities.
- Backlog Conversion: Assess the conversion rate of the $410.2 million backlog into recognized revenue, considering potential delays in customer facility construction and regulatory approvals (Certificates of Need).
- Inventory Levels: Review inventory balances ($35.6 million), which increased by $7.5 million from the prior fiscal year-end, to ensure demand forecasts align with production levels.